ArticleP & T : a peer-reviewed journal for formulary management2015
Conestat alfa (ruconest): first recombinant c1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.
Article in P & T : a peer-reviewed journal for formulary management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Genetically Modified and Gene-Edited Organisms-Objectives, Public Perception and Applications.Biology · 2026Review
- Roles of the Complement System in Peripheral Nerve Injury and Repair.Bioengineering (Basel, Switzerland) · 2026Review
- Bradykinin-induced angioedema in the emergency department.International journal of emergency medicine · 2022Review
- Review
- Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target.Frontiers in immunology · 2020Review
- Self-Management Plans in Patients with Hereditary Angioedema: Strategies, Outcomes and Integration into Clinical Care.Journal of asthma and allergy · 2020Review
- Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research.Drugs in context · 2019Review
- Pharmaceutical Machine Learning: Virtual High-Throughput Screens Identifying Promising and Economical Small Molecule Inhibitors of Complement Factor C1s.Biomolecules · 2018Article
- Angioedema in the emergency department: a practical guide to differential diagnosis and management.International journal of emergency medicine · 2017Review
- Evaluation of staging criteria for disposition and airway intervention in emergency department angioedema patients.Acute medicine & surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.
Identifiers
25673959PMC4315111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.